United Therapeutics Stock Beta

UTHR Stock

USD 316.08 0.00 0.00%

United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

United Therapeutics Company Beta Analysis

United Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current United Therapeutics Beta

0.64

Most of United Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

United Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Beta. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Good Will	Short Term Investments	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	-0.54	0.98	-0.24	0.77	0.65	0.99	0.78	0.94	0.83	0.49	0.47	0.52	-0.7	0.95	0.4	0.98	0.83	0.82	0.83	0.73	0.93	0.91	-0.87
Total Stockholder Equity	0.99		-0.61	0.99	-0.24	0.77	0.58	0.99	0.75	0.93	0.81	0.48	0.43	0.46	-0.67	0.93	0.38	0.99	0.8	0.81	0.8	0.7	0.93	0.92	-0.84
Net Debt	-0.54	-0.61		-0.65	0.13	-0.68	0.13	-0.61	-0.14	-0.33	-0.3	-0.17	-0.24	0.27	0.37	-0.51	-0.2	-0.57	-0.25	-0.47	-0.1	-0.05	-0.42	-0.42	0.21
Retained Earnings	0.98	0.99	-0.65		-0.28	0.8	0.55	0.98	0.75	0.89	0.77	0.54	0.43	0.46	-0.75	0.93	0.27	0.98	0.8	0.85	0.75	0.71	0.9	0.88	-0.82
Accounts Payable	-0.24	-0.24	0.13	-0.28		-0.23	-0.22	-0.27	-0.17	-0.23	-0.01	0.04	0.05	-0.11	0.3	-0.17	0.13	-0.29	-0.25	-0.37	-0.27	-0.28	-0.29	-0.27	0.33
Net Receivables	0.77	0.77	-0.68	0.8	-0.23		0.47	0.79	0.51	0.58	0.58	0.29	0.65	0.18	-0.77	0.8	0.32	0.72	0.53	0.76	0.49	0.49	0.59	0.58	-0.46
Total Liab	0.65	0.58	0.13	0.55	-0.22	0.47		0.6	0.8	0.67	0.64	0.39	0.69	0.81	-0.66	0.7	0.37	0.58	0.8	0.71	0.8	0.76	0.64	0.62	-0.76
Total Current Assets	0.99	0.99	-0.61	0.98	-0.27	0.79	0.6		0.75	0.93	0.79	0.47	0.46	0.47	-0.71	0.94	0.37	0.99	0.81	0.84	0.77	0.7	0.92	0.92	-0.83
Good Will	0.78	0.75	-0.14	0.75	-0.17	0.51	0.8	0.75		0.79	0.65	0.71	0.6	0.7	-0.77	0.8	0.14	0.75	0.83	0.84	0.82	0.8	0.79	0.77	-0.77
Short Term Investments	0.94	0.93	-0.33	0.89	-0.23	0.58	0.67	0.93	0.79		0.8	0.44	0.34	0.61	-0.56	0.87	0.39	0.94	0.82	0.73	0.87	0.75	0.95	0.96	-0.88
Short Term Debt	0.83	0.81	-0.3	0.77	-0.01	0.58	0.64	0.79	0.65	0.8		0.37	0.49	0.61	-0.48	0.82	0.47	0.8	0.67	0.56	0.77	0.75	0.75	0.74	-0.73
Intangible Assets	0.49	0.48	-0.17	0.54	0.04	0.29	0.39	0.47	0.71	0.44	0.37		0.34	0.38	-0.61	0.57	-0.11	0.45	0.47	0.52	0.34	0.45	0.4	0.35	-0.5
Common Stock	0.47	0.43	-0.24	0.43	0.05	0.65	0.69	0.46	0.6	0.34	0.49	0.34		0.36	-0.66	0.65	0.48	0.37	0.49	0.66	0.39	0.38	0.35	0.35	-0.31
Long Term Debt	0.52	0.46	0.27	0.46	-0.11	0.18	0.81	0.47	0.7	0.61	0.61	0.38	0.36		-0.53	0.55	0.15	0.53	0.76	0.54	0.72	0.78	0.55	0.56	-0.76
Treasury Stock	-0.7	-0.67	0.37	-0.75	0.3	-0.77	-0.66	-0.71	-0.77	-0.56	-0.48	-0.61	-0.66	-0.53		-0.76	0.02	-0.67	-0.71	-0.89	-0.53	-0.71	-0.56	-0.55	0.61
Property Plant Equipment	0.95	0.93	-0.51	0.93	-0.17	0.8	0.7	0.94	0.8	0.87	0.82	0.57	0.65	0.55	-0.76		0.47	0.92	0.78	0.84	0.73	0.67	0.82	0.81	-0.8
Current Deferred Revenue	0.4	0.38	-0.2	0.27	0.13	0.32	0.37	0.37	0.14	0.39	0.47	-0.11	0.48	0.15	0.02	0.47		0.32	0.25	0.18	0.32	0.01	0.33	0.33	-0.27
Net Tangible Assets	0.98	0.99	-0.57	0.98	-0.29	0.72	0.58	0.99	0.75	0.94	0.8	0.45	0.37	0.53	-0.67	0.92	0.32		0.82	0.81	0.81	0.73	0.94	0.94	-0.87
Long Term Debt Total	0.83	0.8	-0.25	0.8	-0.25	0.53	0.8	0.81	0.83	0.82	0.67	0.47	0.49	0.76	-0.71	0.78	0.25	0.82		0.88	0.87	0.83	0.89	0.86	-0.91
Capital Surpluse	0.82	0.81	-0.47	0.85	-0.37	0.76	0.71	0.84	0.84	0.73	0.56	0.52	0.66	0.54	-0.89	0.84	0.18	0.81	0.88		0.71	0.73	0.79	0.79	-0.75
Long Term Investments	0.83	0.8	-0.1	0.75	-0.27	0.49	0.8	0.77	0.82	0.87	0.77	0.34	0.39	0.72	-0.53	0.73	0.32	0.81	0.87	0.71		0.84	0.91	0.86	-0.86
Short Long Term Debt	0.73	0.7	-0.05	0.71	-0.28	0.49	0.76	0.7	0.8	0.75	0.75	0.45	0.38	0.78	-0.71	0.67	0.01	0.73	0.83	0.73	0.84		0.75	0.74	-0.79
Net Invested Capital	0.93	0.93	-0.42	0.9	-0.29	0.59	0.64	0.92	0.79	0.95	0.75	0.4	0.35	0.55	-0.56	0.82	0.33	0.94	0.89	0.79	0.91	0.75		0.98	-0.88
Net Working Capital	0.91	0.92	-0.42	0.88	-0.27	0.58	0.62	0.92	0.77	0.96	0.74	0.35	0.35	0.56	-0.55	0.81	0.33	0.94	0.86	0.79	0.86	0.74	0.98		-0.84
Capital Stock	-0.87	-0.84	0.21	-0.82	0.33	-0.46	-0.76	-0.83	-0.77	-0.88	-0.73	-0.5	-0.31	-0.76	0.61	-0.8	-0.27	-0.87	-0.91	-0.75	-0.86	-0.79	-0.88	-0.84

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict United Therapeutics

In accordance with the recently published financial statements, United Therapeutics has a Beta of 0.639. This is 25.7% lower than that of the Biotechnology sector and 54.03% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

United Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.

United Therapeutics is currently under evaluation in beta category among its peers.

United Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

United Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.

		Shares
Alliancebernstein L.p.	2024-12-31	709 K
Dimensional Fund Advisors, Inc.	2024-12-31	620.6 K
Pacer Advisors, Inc.	2024-12-31	597.6 K
Arrowstreet Capital Limited Partnership	2024-12-31	542.4 K
Fuller & Thaler Asset Management Inc	2024-12-31	532.9 K
Northern Trust Corp	2024-12-31	488.9 K
Hhg Plc	2024-12-31	469 K
Norges Bank	2024-12-31	430.1 K
Genworth Financial Wealth Mgmt Inc	2024-12-31	429.2 K
Wealthfront Advisers Llc	2024-12-31	18.3 M
Blackrock Inc	2024-12-31	5.4 M

As returns on the market increase, United Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding United Therapeutics is expected to be smaller as well.

United Fundamentals

	Return On Equity	0.19
	Return On Asset	0.12
	Profit Margin	0.42 %
	Operating Margin	0.49 %
	Current Valuation	10.83 B
	Shares Outstanding	44.91 M
	Shares Owned By Insiders	1.83 %
	Shares Owned By Institutions	98.17 %
	Number Of Shares Shorted	2.07 M
	Price To Earning	23.49 X
	Price To Book	2.14 X
	Price To Sales	4.80 X
	Revenue	2.88 B
	Gross Profit	2.57 B
	EBITDA	1.65 B
	Net Income	1.2 B
	Cash And Equivalents	2.26 B
	Cash Per Share	49.55 X
	Total Debt	300 M
	Debt To Equity	0.18 %
	Current Ratio	8.10 X
	Book Value Per Share	143.74 X
	Cash Flow From Operations	1.33 B
	Short Ratio	4.69 X
	Earnings Per Share	24.64 X
	Price To Earnings To Growth	1.43 X
	Target Price	400.54
	Number Of Employees	1.3 K
	Beta	0.64
	Market Capitalization	13.8 B
	Total Asset	7.36 B
	Retained Earnings	7.22 B
	Working Capital	3.14 B
	Current Asset	1.28 B
	Current Liabilities	440.82 M
	Net Asset	7.36 B

About United Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against United Stock

0.71	IVA	Inventiva Sa	Pair Corr
0.51	LLY	Eli Lilly	Pair Corr
0.48	KRYS	Krystal Biotech	Pair Corr
0.42	PBH	Prestige Brand Holdings	Pair Corr
0.4	MGTX	MeiraGTx Holdings PLC Downward Rally	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC